Predictive Capital Expenditures vs Depreciation Analysis

POAI Stock

USD 0.81 0.03 3.85%

Predictive Oncology financial indicator trend analysis is much more than just breaking down Predictive Oncology prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Predictive Oncology is a good investment. Please check the relationship between Predictive Oncology Capital Expenditures and its Depreciation accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.

Capital Expenditures vs Depreciation

Capital Expenditures vs Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Predictive Oncology Capital Expenditures account and Depreciation. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Predictive Oncology's Capital Expenditures and Depreciation is 0.82. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Depreciation in the same time period over historical financial statements of Predictive Oncology, assuming nothing else is changed. The correlation between historical values of Predictive Oncology's Capital Expenditures and Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Predictive Oncology are associated (or correlated) with its Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation has no effect on the direction of Capital Expenditures i.e., Predictive Oncology's Capital Expenditures and Depreciation go up and down completely randomly.

Correlation Coefficient

0.82

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by Predictive Oncology to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Predictive Oncology operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Depreciation

Depreciation indicates how much of Predictive Oncology value has been used up. For tax purposes Predictive Oncology can deduct the cost of the tangible assets it purchases as business expenses. However, Predictive Oncology must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Most indicators from Predictive Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Predictive Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.As of now, Predictive Oncology's Tax Provision is decreasing as compared to previous years. The Predictive Oncology's current Enterprise Value is estimated to increase to about 12.6 M, while Selling General Administrative is projected to decrease to under 7.1 M.

	2021	2022	2023	2024 (projected)
Gross Profit	933.7K	1.0M	1.1M	575.4K
Total Revenue	1.4M	1.5M	1.8M	899.7K

Gross Profit Total Revenue

Predictive Oncology fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Net Receivables	Inventory
Total Assets		0.18	0.21	0.32	0.97	0.62	0.54	-0.76	-0.69	0.32	0.86	0.73	0.86	-0.25	0.59	0.06	0.61	0.75	0.31	0.52	0.87	0.14	0.73	0.0	0.25	0.56
Short Long Term Debt Total	0.18		0.41	0.78	-0.02	0.58	-0.09	0.44	-0.27	0.55	-0.27	0.71	-0.27	-0.29	-0.05	0.32	0.0	0.23	0.81	0.28	-0.26	0.93	0.63	-0.39	0.15	0.06
Other Current Liab	0.21	0.41		0.81	0.02	0.43	0.26	0.1	-0.33	0.7	0.0	0.4	0.0	0.12	0.11	0.09	0.0	0.28	0.79	0.27	0.01	0.42	0.37	0.14	-0.03	0.38
Total Current Liabilities	0.32	0.78	0.81		0.08	0.54	0.1	0.28	-0.3	0.87	-0.11	0.75	-0.11	-0.07	0.03	0.16	-0.07	0.27	0.98	0.29	-0.1	0.77	0.67	-0.08	0.02	0.15
Total Stockholder Equity	0.97	-0.02	0.02	0.08		0.49	0.52	-0.87	-0.63	0.12	0.93	0.57	0.93	-0.24	0.59	-0.02	0.65	0.71	0.07	0.45	0.93	-0.05	0.6	0.03	0.26	0.54
Property Plant And Equipment Net	0.62	0.58	0.43	0.54	0.49		0.51	-0.28	-0.85	0.37	0.4	0.61	0.4	-0.2	0.71	0.69	0.46	0.84	0.62	0.87	0.41	0.34	0.58	-0.17	0.18	0.57
Current Deferred Revenue	0.54	-0.09	0.26	0.1	0.52	0.51		-0.65	-0.81	0.1	0.67	0.1	0.67	0.01	0.85	0.4	0.52	0.8	0.15	0.75	0.67	-0.25	-0.01	0.17	0.19	0.66
Net Debt	-0.76	0.44	0.1	0.28	-0.87	-0.28	-0.65		0.55	0.17	-0.98	-0.11	-0.98	0.12	-0.66	0.02	-0.63	-0.62	0.28	-0.41	-0.98	0.48	-0.16	-0.16	-0.13	-0.58
Retained Earnings	-0.69	-0.27	-0.33	-0.3	-0.63	-0.85	-0.81	0.55		-0.23	-0.63	-0.43	-0.63	0.25	-0.91	-0.61	-0.71	-0.99	-0.37	-0.94	-0.64	-0.05	-0.33	0.16	-0.38	-0.81
Accounts Payable	0.32	0.55	0.7	0.87	0.12	0.37	0.1	0.17	-0.23		-0.04	0.68	-0.04	-0.06	0.08	0.15	-0.1	0.22	0.85	0.26	-0.04	0.52	0.5	-0.08	-0.14	0.17
Cash	0.86	-0.27	0.0	-0.11	0.93	0.4	0.67	-0.98	-0.63	-0.04		0.28	1.0	-0.16	0.68	0.01	0.66	0.69	-0.1	0.47	1.0	-0.32	0.33	0.13	0.16	0.63
Non Current Assets Total	0.73	0.71	0.4	0.75	0.57	0.61	0.1	-0.11	-0.43	0.68	0.28		0.28	-0.23	0.18	0.09	0.21	0.47	0.73	0.34	0.28	0.7	0.93	-0.15	0.22	0.18
Cash And Short Term Investments	0.86	-0.27	0.0	-0.11	0.93	0.4	0.67	-0.98	-0.63	-0.04	1.0	0.28		-0.16	0.68	0.01	0.66	0.69	-0.1	0.47	1.0	-0.32	0.33	0.13	0.15	0.63
Common Stock Total Equity	-0.25	-0.29	0.12	-0.07	-0.24	-0.2	0.01	0.12	0.25	-0.06	-0.16	-0.23	-0.16		-0.15	-0.04	-0.42	-0.27	-0.07	-0.17	-0.18	-0.26	-0.2	0.94	-0.25	-0.4
Common Stock Shares Outstanding	0.59	-0.05	0.11	0.03	0.59	0.71	0.85	-0.66	-0.91	0.08	0.68	0.18	0.68	-0.15		0.66	0.62	0.92	0.11	0.93	0.69	-0.31	0.07	-0.06	0.19	0.72
Non Current Liabilities Total	0.06	0.32	0.09	0.16	-0.02	0.69	0.4	0.02	-0.61	0.15	0.01	0.09	0.01	-0.04	0.66		0.13	0.56	0.3	0.81	0.01	-0.02	-0.04	-0.21	-0.06	0.35
Other Current Assets	0.61	0.0	0.0	-0.07	0.65	0.46	0.52	-0.63	-0.71	-0.1	0.66	0.21	0.66	-0.42	0.62	0.13		0.72	-0.04	0.53	0.69	-0.11	0.21	-0.25	0.68	0.78
Other Stockholder Equity	0.75	0.23	0.28	0.27	0.71	0.84	0.8	-0.62	-0.99	0.22	0.69	0.47	0.69	-0.27	0.92	0.56	0.72		0.33	0.92	0.71	0.02	0.38	-0.15	0.37	0.79
Total Liab	0.31	0.81	0.79	0.98	0.07	0.62	0.15	0.28	-0.37	0.85	-0.1	0.73	-0.1	-0.07	0.11	0.3	-0.04	0.33		0.39	-0.09	0.74	0.64	-0.1	0.01	0.21
Property Plant And Equipment Gross	0.52	0.28	0.27	0.29	0.45	0.87	0.75	-0.41	-0.94	0.26	0.47	0.34	0.47	-0.17	0.93	0.81	0.53	0.92	0.39		0.48	-0.01	0.21	-0.16	0.18	0.67
Total Current Assets	0.87	-0.26	0.01	-0.1	0.93	0.41	0.67	-0.98	-0.64	-0.04	1.0	0.28	1.0	-0.18	0.69	0.01	0.69	0.71	-0.09	0.48		-0.31	0.33	0.11	0.2	0.65
Short Term Debt	0.14	0.93	0.42	0.77	-0.05	0.34	-0.25	0.48	-0.05	0.52	-0.32	0.7	-0.32	-0.26	-0.31	-0.02	-0.11	0.02	0.74	-0.01	-0.31		0.67	-0.32	0.14	-0.11
Intangible Assets	0.73	0.63	0.37	0.67	0.6	0.58	-0.01	-0.16	-0.33	0.5	0.33	0.93	0.33	-0.2	0.07	-0.04	0.21	0.38	0.64	0.21	0.33	0.67		-0.09	0.21	0.14
Common Stock	0.0	-0.39	0.14	-0.08	0.03	-0.17	0.17	-0.16	0.16	-0.08	0.13	-0.15	0.13	0.94	-0.06	-0.21	-0.25	-0.15	-0.1	-0.16	0.11	-0.32	-0.09		-0.2	-0.27
Net Receivables	0.25	0.15	-0.03	0.02	0.26	0.18	0.19	-0.13	-0.38	-0.14	0.16	0.22	0.15	-0.25	0.19	-0.06	0.68	0.37	0.01	0.18	0.2	0.14	0.21	-0.2		0.33
Inventory	0.56	0.06	0.38	0.15	0.54	0.57	0.66	-0.58	-0.81	0.17	0.63	0.18	0.63	-0.4	0.72	0.35	0.78	0.79	0.21	0.67	0.65	-0.11	0.14	-0.27	0.33

Click cells to compare fundamentals

Predictive Oncology Account Relationship Matchups

Predictive Oncology fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	22.4M	13.1M	43.8M	25.7M	14.4M	9.5M
Short Long Term Debt Total	5.5M	5.9M	879.3K	180.3K	2.9M	1.9M
Other Current Liab	2.4M	2.9M	1.4M	2.1M	1.6M	1.6M
Total Current Liabilities	10.9M	9.3M	3.2M	3.9M	4.0M	4.0M
Total Stockholder Equity	11.2M	2.6M	40.3M	21.8M	8.3M	5.0M
Property Plant And Equipment Net	2.2M	5.2M	3.3M	2.0M	4.0M	4.2M
Current Deferred Revenue	40.4K	53.0K	187.0K	602.1K	308.1K	323.5K
Net Debt	5.4M	5.2M	(27.3M)	(21.9M)	(5.9M)	(5.6M)
Retained Earnings	(82.5M)	(108.4M)	(128.0M)	(153.8M)	(167.8M)	(159.4M)
Accounts Payable	3.2M	1.4M	1.0M	943.5K	1.3M	1.1M
Cash	150.8K	678.3K	28.2M	22.1M	8.7M	4.7M
Non Current Assets Total	21.6M	11.5M	14.3M	2.4M	4.3M	4.1M
Cash And Short Term Investments	150.8K	678.3K	28.2M	22.1M	8.7M	4.7M
Common Stock Total Equity	69.4K	140.9K	40.6K	198.0K	178.2K	275.4K
Common Stock Shares Outstanding	143.5K	597.5K	2.7M	3.6M	4.0M	4.2M
Liabilities And Stockholders Equity	22.4M	13.1M	43.8M	25.7M	14.4M	9.5M
Non Current Liabilities Total	270.3K	1.1M	265.1K	86.1K	2.2M	2.3M
Other Current Assets	160.2K	289.5K	513.8K	526.8K	521.7K	263.4K
Other Stockholder Equity	93.7M	110.8M	167.6M	174.8M	176.0M	184.8M
Total Liab	11.1M	10.4M	3.5M	4.0M	6.1M	4.6M
Property Plant And Equipment Gross	2.2M	3.8M	3.3M	4.9M	7.6M	7.9M
Total Current Assets	798.3K	1.5M	29.5M	23.4M	10.1M	5.5M
Short Term Debt	5.3M	5.0M	639.7K	188.5K	667.8K	634.4K
Intangible Assets	3.6M	3.4M	4.0M	253.9K	252.5K	239.8K
Common Stock	40.6K	198.0K	656.1K	787.6K	40.6K	38.6K
Net Receivables	297.1K	256.9K	354.2K	331.2K	333.7K	270.7K
Inventory	190.2K	289.5K	387.7K	430.5K	494.4K	299.1K
Non Currrent Assets Other	(21.6M)	116.3K	167.1K	75.6K	124.1K	130.3K
Accumulated Other Comprehensive Income	(273.8K)	(358.8K)	(771.6K)	(792.0)	(712.8)	(748.44)
Capital Surpluse	57.4M	63.0M	93.7M	110.8M	127.5M	70.3M
Property Plant Equipment	2.2M	5.2M	3.3M	2.0M	2.4M	1.7M
Net Tangible Assets	(8.1M)	(3.6M)	29.4M	21.5M	24.7M	26.0M
Net Invested Capital	16.0M	7.1M	40.3M	21.8M	8.4M	15.4M
Net Working Capital	(10.1M)	(7.8M)	26.2M	19.5M	6.1M	5.2M
Capital Stock	76.4K	198.8K	656.9K	788.4K	41.4K	39.3K

Currently Active Assets on Macroaxis

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C
MSFT	Microsoft
GM	General Motors

When determining whether Predictive Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Predictive Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Predictive Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Predictive Oncology Stock:

How To Invest In Predictive

Details

Is Predictive Stock a good investment?

Details

What is Predictive Oncology's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.

You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.96)

Revenue Per Share

0.416

Quarterly Revenue Growth

(0.43)

Return On Assets

(0.56)

Return On Equity

(1.49)

The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Predictive Capital Expenditures vs Depreciation Analysis

Capital Expenditures vs Depreciation

Capital Expenditures vs Depreciation Correlation Analysis

Correlation Coefficient

Capital Expenditures

Depreciation

Predictive Oncology fundamental ratios Correlations

Predictive Oncology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Predictive Oncology fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 0.98	Total Current Liabilities
Total Stockholder Equity	+ 0.97	Total Assets
Common Stock	+ 0.94	Common Stock Total Equity

Other Stockholder Equity	- 0.99	Retained Earnings
Total Current Assets	- 0.98	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Property Plant And Equipment Gross	- 0.94	Retained Earnings
Common Stock Shares Outstanding	- 0.91	Retained Earnings